Tim Oldham

CEO at AdAlta Ltd

Speaker

AdAlta Ltd is an Australian drug discovery and development company using its proprietary i-body (human single domain antibody) platform to solve drug targeting challenges that traditional antibodies cannot.

AdCella Pty Ltd, an AdAlta subsidiary, provides a pathway into western regulated markets for cellular immunotherapies originating in Asia. AdCella leverages privileged access to Australia's globally recognised and FDA compliant cell therapy ecosystem at lower cost than US. AdCella is a force multiplier for Asian cellular therapies, adding value by licensing ex-Asia rights, establishing an FDA compliant manufacturing platform, securing US IND approval and conducting Phase I clinical trials in a return for a share of the enhanced economic value of the asset. Partners will also have access to the AdAlta i-body platform for pipeline products.

AdSolis Pty Ltd is AdAlta's subsidiary developing novel anti-fibrotic AD-214.